Skip to main content
FDA fast-tracks depressive disorder drug from Sage
5/19/2017

Sage Therapeutics' drug candidate SAGE-217 has been granted fast-track designation by the FDA as a treatment for major depressive disorder. The company has an ongoing midstage clinical development study of the drug, including four trials for movement and mood disorders.

Full Story: